[Infectious risks of new immunosuppressive biologicals : which prophylaxis and when ?]

Biological treatments are a revolution in the management of many diseases and their development, with the marketing of many new biologics, challenges practitioners in assessing the risk of infectious complications. A rigorous evaluation is required with the introduction of prophylaxis, vaccinations or specific clinical monitoring.